Effects of chicken collagen hydrolysate on blood pressure and endothelial function in subjects with high-normal blood pressure or stage I hypertension: a randomized, double-blind, placebo-controlled, parallel-group study

Effects of chicken collagen hydrolysate on blood pressure and endothelial function in subjects with high-normal blood pressure or stage I hypertension: a randomized, double-blind, placebo-controlled, parallel-group study - Effects of chicken collagen hydrolysate on blood pressure and endothelial function in subjects with high-normal blood pressure or stage I hypertension: a randomized, double-blind, placebo-controlled, parallel-group study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026172

Enrollment

Registered

2017-10-08

Start date

2016-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Chicken collagen hydrolysate (high dose) (2.9 g(3.4 g/sachet)/day, weeks 12 during the intervention) Chicken collagen hydrolysate (low dose) (1.7 g(3.4 g/sachet)/day, weeks 12 during the intervent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adult (aged 20-65) 2) Subjects with high-normal blood pressure or mild hypertension (according to guidelines for the management of hypertension 2014) 3) Subjects with low FMD value

Exclusion criteria

Exclusion criteria: 1) Taking pharmaceutical agent, functional food, or supplement that may affect the study 2) Ineligible subjects with abnormal laboratory value or cardiopulmonary function 3) Sensitive to test product or other foods 4) In treatment 5) History of severe diseases (diabetes, liver, kidney, heart (especially coronary artery disease, heart failure)) judged to be inappropriate for this study 6) Extreme deviations from the reference range of anthropometrics, physical examination or laboratory value 7) Change of life style during the test period (ex. a night shift, going abroad) may affect the study. 8) Participation in any other clinical trial within 30 days before the study. 9) In pregnancy or lactating 10) Ineligible subjects for the study according to the judgement by lifestyle questionnaire 11) Unlikely to obey the restriction item (prohibited matter) during the study 12) Ineligible subjects for the study according to the judgement by chief investigator

Design outcomes

Primary

Measure	Time frame
Changes of flow-mediated dilatation (FMD), blood pressure at 4, 8, 12 weeks after the intervention.	—

Countries

Japan

Contacts

Public ContactSaki Fukuchi

TTC CO., LTD. Clinical Research Planning Department

s.fukuchi@ttc-tokyo.co.jp03-5459-5329

Outcome results